Accession Number:



The Thoc1 Ribonucleoprotein as a Novel Biomarker for Prostate Cancer Treatment Assignment

Descriptive Note:

Technical Report,15 Sep 2016,14 Sep 2017

Corporate Author:

Health Research, Inc. Buffalo United States

Personal Author(s):

Report Date:


Pagination or Media Count:



Active surveillance AS is an option for men with low risk prostate cancer in order to reduce over treatment, but few men choose it because current prognostic indicators are imperfect. The objectives of this research are to test whether pThoc1 can improve the assignment of prostate cancer patients to therapy. We have made significant progress on the goals articulated in the Statement of Work. IRBHRPO approval has been obtained for construction and use of new TMAs PI Mohler and Goodrich. The TMAs from PCaP have been obtained PI Mohler and Goodrich. Pathology analysis of 1146 patient specimens and construction of TMAs are completed and the TMA sections were requested, pending immunostaining PI Mohler. Optimization of TMA staining is complete and staining of PCaP TMAs initiated PI Goodrich.

Subject Categories:

  • Medicine and Medical Research

Distribution Statement: